Replies to post #247647 on Biotech Values

[DewDiligence]

Re: GSK, PFE RSV vaccines

The entire [ACIP] thing is beyond bizarre - when you read headlines the vote was 9-5 to recommend vaccination in >65 year olds but 13-0 with one abstention for 60-64?? You would think the opposite risk benefit favors older - so the only conclusion is the 5 against in the >65 year olds wanted a universal recommendation.

The seemingly strange vote for the 65+ age group came about because that voting question did not having an upper bound on the age, and five panelists thought there were too few subjects in the trials who were much older than 65 to issue a recommendation for an open-ended age range. Had the question asked about age 65-75 (instead of 65+), the vote probably would’ve been unanimous.

This is dumb and unduly literal behavior by the panelists, IMO.